

Rec'd PCT/PTO 15 APR 2002

Patent  
Attorney's Docket No. 033392-001

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of )  
)  
Eberhard HILDT et al. ) Group Art Unit: Unassigned  
)  
Application No.: 09/830,981 ) Examiner: Unassigned  
)  
Filed: May 3, 2001 )  
)  
For: POLYPEPTIDE MEDIATING CELL )  
PERMEABILITY )

**PRELIMINARY AMENDMENT**

**BOX SEQUENCE**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to examination, please amend the above-captioned application as follows:

**IN THE SPECIFICATION:**

Kindly amend the specification as follows:

Page 8, replace the paragraph beginning at line 9, with the following rewritten paragraph:

--**Figure 1** shows the amino acid and DNA sequences (SEQ ID NOS.:1 AND 2) of a cell permeability-mediating polypeptide according to the invention (CPP).--

Application No. 09/830,981  
Attorney's Docket No. 033392-001

Page 8, replace the paragraph beginning at line 17, with the following rewritten paragraph:

--**Figure 3** (SEQ ID NOS.: 3-10) shows the conservation of the amino acid sequence between various HBV subtypes as well as the hydropathy profile.--

Page 8, replace the paragraph beginning at line 20, with the following rewritten paragraph:

--**Figure 4** (SEQ ID NOS.:11-16) shows amphiphilic motives in the PreS region of various avian hepadnaviruses.--

Page 8, replace the paragraph beginning at line 22, with the following rewritten paragraph:

**Figure 5** (SEQ ID NOS.:17-20) shows amphiphilic motives in the PreS2 region of various hepadnaviruses of rodents.--

Application No. 09/830,981  
Attorney's Docket No. 033392-001

**REMARKS**

Entry of the foregoing amendment(s) is respectfully requested.

Should the Examiner have any questions concerning the subject application, a telephone call to the undersigned would be appreciated.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 

Teresa Stanek Rea  
Registration No. 30,427

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

**Date: April 15, 2002**

Application No. 09/830,981  
Attorney's Docket No. 033392-001

**Attachment to Preliminary Amendment dated April 15, 2002**  
**Amendments to Specification**

**IN THE SPECIFICATION:**

Kindly amend the specification as follows:

Page 8, replace the paragraph beginning at line 9, with the following rewritten paragraph:

--**Figure 1** shows the amino acid and DNA sequences (SEQ ID NOS.: 1 AND 2) of a cell permeability-mediating polypeptide according to the invention (CPP).--

Page 8, replace the paragraph beginning at line 17, with the following rewritten paragraph:

--**Figure 3** (SEQ ID NOS.: 3-10) shows the conservation of the amino acid sequence between various HBV subtypes as well as the hydropathy profile.--

Page 8, replace the paragraph beginning at line 20, with the following rewritten paragraph:

--**Figure 4** (SEQ ID NOS.: 11-16) shows amphiphilic motives in the PreS region of various avian hepadnaviruses.--

Application No. 09/830,981  
Attorney's Docket No. 033392-001

**Attachment to Preliminary Amendment dated April 15, 2002**  
**Amendments to Specification**

Page 8, replace the paragraph beginning at line 22, with the following rewritten paragraph:

**Figure 5** (SEQ ID NOS.:17-20) shows amphiphilic motives in the PreS2 region of various hepadnaviruses of rodents.--



Rec'd PCT/PTO 15 APR 2002

Patent  
Attorney's Docket No. 033392-001

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	
	)	
Eberhard HILDT et al	)	Group Art Unit: 1653
	)	
Serial No.: 09/830,981	)	Examiner: Not yet assigned
	)	
Filed: May 3, 2001	)	<b>ATTENTION: BOX SEQUENCE</b>
	)	
For: Polypeptide Mediating Cell	)	
Permeability	)	

**REPLY**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Notification of Missing Requirements Under 35 U.S.C. 371  
dated February 14, 2002, please amend the above-identified application as follows:

**IN THE SPECIFICATION:**

In compliance with 37 C.F.R. §1.823(a), please insert the attached paper copy  
of the "Sequence Listing" after the last page of the above-identified application.

Serial No.: 09/830,981

REMARKS


The paper copy of the Sequence Listing for the subject application, is by this amendment, added after the last page of the application.

Favorable consideration on the merits is respectfully requested.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By

  
\_\_\_\_\_  
Teresa Stanek Rea  
Registration No. 30,427

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Date: *15 April 2002*



Patent  
Attorney's Docket No. 033392-001

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	
	)	
Eberhard HILDT et al	)	Group Art Unit: 1653
	)	
Serial No.: 09/830,981	)	Examiner: Not yet assigned
	)	
Filed: May 3, 2001	)	<b>ATTENTION: BOX SEQUENCE</b>
	)	
For: Polypeptide Mediating Cell	)	
Permeability	)	

**DECLARATION PURSUANT TO**  
**37 C.F.R. §§1.821-1.825**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

I, Teresa Stanek Rea, declare as follows:


1. That the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same in compliance with §1.821(f).
2. That the submission, filed in accordance with 37 C.F.R. §1.821(g)[or (h)], herein does not include new matter [or go beyond the disclosure in the international application].




Serial No.: 09/830,981

I hereby declare that all statements made herein of my own knowledge are true and that all statements were made on information and belief and are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

15 April 2002  
Date

  
\_\_\_\_\_  
Teresa Stanek Rea  
Registration No. 30,427



033392-001.ST25

SEQUENCE LISTING

<110> Eberhard Hildt  
Stephanie Schmidt

<120> Polypeptide Mediating Cell Permeability

<130> 033392-001

<140> US 09/830,981

<141> 2001-05-03

<150> PCT/DE99/03506

<151> 1999-11-03

<150> DE 198 50 718.6

<151> 1998-11-03

<160> 20

<170> PatentIn Ver. 2.1

<210> 1

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
Cell permeability mediating polypeptide

<220>

<221> CDS

<222> (1)..(36)

<400> 1

ccc tta tgc tca atc ttc tgc agg att ggg gac cct  
Pro Leu Ser Ser Ile Phe Ser Arg Ile Gly Asp Pro  
1 5 10

36

<210> 2

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
Cell permeability mediating polypeptide

<400> 2

Pro Leu Ser Ser Ile Phe Ser Arg Ile Gly Asp Pro  
1 5 10

<210> 3  
<211> 36  
<212> DNA  
<213> Hepadnavirus

<220>  
<221> CDS  
<222> (1)..(36)

<400> 3

ccc tta tcg tca atc ttc tcg agg att ggg gac cct  
Pro Leu Ser Ser Ile Phe Ser Arg Ile Gly Asp Pro  
1 5 10

36

<210> 4  
<211> 12  
<212> PRT  
<213> Hepadnavirus

<400> 4

Pro Leu Ser Ser Ile Phe Ser Arg Ile Gly Asp Pro  
1 5 10

<210> 5  
<211> 36  
<212> DNA  
<213> Hepadnavirus

<220>  
<221> CDS  
<222> (1)..(36)

<400> 5

ccc ata tcg tca atc ttc tcg agg att ggg gac cct  
Pro Ile Ser Ser Ile Phe Ser Arg Ile Gly Asp Pro  
1 5 10

36

<210> 6  
<211> 12  
<212> PRT  
<213> Hepadnavirus

<400> 6

Pro Ile Ser Ser Ile Phe Ser Arg Ile Gly Asp Pro

1

5

10

<210> 7  
 <211> 36  
 <212> DNA  
 <213> Hepadnavirus

<220>  
 <221> CDS  
 <222> (1)..(36)

<400> 7

ccc ata tcg tca atc ttc tcg agg act ggg gac cct  
 Pro Ile Ser Ser Ile Phe Ser Arg Thr Gly Asp Pro  
           1                          5                          10

36

<210> 8  
 <211> 12  
 <212> PRT  
 <213> Hepadnavirus

<400> 8

Pro Ile Ser Ser Ile Phe Ser Arg Thr Gly Asp Pro  
           1                          5                          10

<210> 9  
 <211> 36  
 <212> DNA  
 <213> Hepadnavirus

<220>  
 <221> CDS  
 <222> (1)..(36)

<400> 9

cac atc tcg tca atc tcc gcg agg act ggg gac cct  
 His Ile Ser Ser Ile Ser Ala Arg Thr Gly Asp Pro  
           1                          5                          10

36

<210> 10  
 <211> 12  
 <212> PRT  
 <213> Hepadnavirus

<400> 10

His Ile Ser Ser Ile Ser Ala Arg Thr Gly Asp Pro  
1 5 10

<210> 11  
<211> 12  
<212> PRT  
<213> Hepadnavirus

<400> 11

Leu Leu Asn Gln Leu Ala Gly Arg Met Ile Pro Lys  
1 5 10

<210> 12  
<211> 12  
<212> PRT  
<213> Hepadnavirus

<400> 12

Pro Leu Ser Ser Ile Phe Ser Arg Ile Gly Asp Pro  
1 5 10

<210> 13  
<211> 12  
<212> PRT  
<213> Hepadnavirus

<400> 13

Thr Ile Asp His Val Leu Asp His Val Gln Thr Met  
1 5 10

<210> 14  
<211> 12  
<212> PRT  
<213> Hepadnavirus

<400> 14

Pro Leu Ser Ser Ile Phe Ser Arg Ile Gly Asp Pro  
1 5 10

<210> 15

<211> 12  
<212> PRT  
<213> Hepadnavirus

<400> 15

Thr Ile Gln His Val Met Asp His Ile Asp Ser Val  
1 5 10

<210> 16  
<211> 12  
<212> PRT  
<213> Hepadnavirus

<400> 16

Pro Leu Ser Ser Ile Phe Ser Arg Ile Gly Asp Pro  
1 5 10

<210> 17  
<211> 12  
<212> PRT  
<213> Hepadnavirus

<400> 17

Thr Leu Ser Pro Val Val Pro Thr Val Ser Thr Ile  
1 5 10

<210> 18  
<211> 12  
<212> PRT  
<213> Hepadnavirus

<400> 18

Pro Leu Ser Ser Ile Phe Ser Arg Ile Gly Asp Pro  
1 5 10

<210> 19  
<211> 12  
<212> PRT  
<213> Hepadnavirus

<400> 19

<400> 20

Page 6